Edition:
United States

Celgene Corp (CELG.O)

CELG.O on Nasdaq

112.19USD
29 Jul 2016
Change (% chg)

$0.93 (+0.84%)
Prev Close
$111.26
Open
$110.66
Day's High
$112.43
Day's Low
$110.50
Volume
5,486,248
Avg. Vol
4,512,176
52-wk High
$136.40
52-wk Low
$92.98

Latest Key Developments (Source: Significant Developments)

Celgene prices $8 billion of senior unsecured notes
Tuesday, 4 Aug 2015 07:30am EDT 

Celgene Corporation:Announces the pricing of five series of senior unsecured notes for an aggregate principal amount of $8.0 billion.  Full Article

Celgene Corp raises FY 2015 adjusted EPS guidance
Thursday, 23 Jul 2015 07:30am EDT 

Celgene Corp:Sees FY 2015 Adjusted EPS Guidance Raised.Sees FY 2015 total net product sales are expected to be in the range of $9.0 billion to $9.5 billion.Sees FY 2015 REVLIMID net sales are expected to be in the range of $5.6 billion to $5.7 billion.Sees FY 2015 ABRAXANE net sales are expected to be in the range of $1.0 billion to $1.25 billion.Sees FY 2015 Adjusted diluted EPS is expected to be in the range of $4.75 to $4.85, up from the original range of $4.60 to $4.75.Sees FY 2015 GAAP diluted EPS to be in the range of $2.17 to $2.46, lowered from the original range of $2.97 to $3.1.  Full Article

Celgene Corp to acquire Receptos
Tuesday, 14 Jul 2015 04:58pm EDT 

Celgene Corp:To acquire Receptos, advancing in immune-inflammatory diseases.Says Celgene will pay $232.00 per share in cash, or a total of approximately $7.2 billion.Celgene will acquire all of the outstanding shares of common stock of Receptos through a tender offer, followed by a second-step merger.Says transaction has been approved by the boards of directors of both companies.Says Celgene expects to fund the transaction through a combination of existing cash and new debt.Says j.p. morgan and Citi are acting as financial advisors to Celgene on the transaction.  Full Article

Celgene Corp and Juno announces ten-year collaboration
Monday, 29 Jun 2015 04:05pm EDT 

Celgene Corp:Celgene and Juno announce ten-year collaboration to advance potentially groundbreaking immunotherapies for patients with cancer and autoimmune diseases.Says gains option to commercialize Juno programs outside North America and co-promote certain programs globally.To make initial payment of approximately $1 billion which includes the purchase of 9.1 million shares of Juno stock at $93.00 per share.Says Juno gains option to co-develop and co-promote select Celgene programs.Says additionally, subject to additional obligations, Celgene may select a third program.Says parties will share global costs and profits with 70% allocated to Celgene and 30% allocated to Juno.Will lead global development and commercialization, subject to a Juno Co promote option in the US and certain EU territories.Says has entered into a standstill agreement and agreed to certain lock-up provisions on its share ownership.Says transaction has been approved by the boards of directors of both companies.Says Celgene and Juno currently expect to complete the transaction during the third quarter of 2015.  Full Article

Celgene Corp announces additional $4 billion share repurchase authorization
Wednesday, 17 Jun 2015 07:30am EDT 

Celgene Corp:Says its Board of Directors has authorized the repurchase of up to an additional $4.0 billion of the company's common stock.This open-ended program is effective immediately.The company now has a total of about $5.2 billion remaining from previous authorizations plus the new authorization.  Full Article

Celgene Corp updates results from mm-020/ifm 07-01
Friday, 12 Jun 2015 07:30am EDT 

Celgene Corp:Updated results from mm-020/ifm 07-01 (first) study of revlimid presented at European hematology annual congress.Updated analysis of progression-free survival demonstrated median of 26 months for patients treated with continuous rd versus 21.9 months for mpt.Incidence of solid tumors was similar in continuous rd and mpt arms (3.4 pct and 3.3 pct, respectively) and 5.9 pct in rd18 arm.Says updated analysis of safety in the continuous rd arm remained similar with extended follow-up to previously reported data.  Full Article

Celgene Corp and Lycera Corp says exclusive strategic collaboration
Tuesday, 9 Jun 2015 07:00am EDT 

Celgene Corp:Lycera and Celgene announce an exclusive strategic collaboration to advance novel immune modulators.Lycera corp says under the terms of the agreement, lycera receives an $82.5 million upfront cash payment.Lycera corp says upfront payment includes an exclusive option for Celgene to license lycera's portfolio of ex vivo rorgamma agonist compounds.Lycera corp says lycera has the potential to receive near term payments of an additional $22.5 million.Lycera says Celgene gets exclusive right to buy lycera upon conclusion of option period or achievement by lycera of pre-specified clinical milestones.Lycera says during the option period, lycera will retain full control of its research and development programs.Lycera says following the exercise of the option to acquire lycera, shareholders will be also eligible to receive future success-based milestones.  Full Article

Analysis of Phase II Data for Celgene Corp's Investigational Oral GED-0301 in patients with Active Crohn's Disease presented at digestive disease week
Tuesday, 19 May 2015 08:15am EDT 

Celgene Corp:Says that a post-hoc subgroup analysis of a double-blind, placebo-controlled, randomized, multicenter phase II trial of GED-0301 (mongersen) in patients with active Crohn's disease was presented at Digestive Disease Week (DDW) in Washington, D.C.Patients with more severe Crohn's disease or longer disease duration treated with GED-0301 160 mg experienced clinical remission and response rates greater than placebo.Phase II trial enrolled 166 adult patients with moderate-to-severe Crohn's disease with documented inflammatory lesions in the terminal ileum and/or right colon.Patients with known lesions in the stomach, proximal small intestine, transverse colon, and/or left colon, strictures, fistulae, perianal disease, extraintestinal manifestations, active or recent infections or a history of malignancy were excluded.Patients were randomly assigned to receive treatment for two weeks with one of three daily doses of GED-0301 or placebo and then evaluated for responses at days 15, 28 and 84.Primary efficacy endpoint of the study was the percentage of patients with clinical remission, defined as a CDAI score below 150 at day 15, which was maintained at day 28.Secondary endpoints included clinical response defined as a reduction of CDAI score of 100 points or 70 points at day 15 and day 28.  Full Article

Celgene Corporation and Acceleron Pharma Inc announces FDA fast track designation granted to Luspatercept
Monday, 18 May 2015 07:30am EDT 

Celgene Corporation and Acceleron Pharma Inc:Says FDA has granted Fast Track designations to luspatercept for two separate indications; the use of luspatercept for the treatment of patients with transfusion dependent beta-thalassemia and the use of luspatercept for the treatment of patients with non-transfusion dependent beta-thalassemia.Says Celgene and Acceleron are jointly developing luspatercept.  Full Article

Celgene Corp announces analysis of REVLIMID (Lenalidomide) in patients with non-del-5Q MDS demonstrated improved health related quality of life measures
Friday, 1 May 2015 07:30am EDT 

Celgene Corp:Announced results from pre-specified secondary endpoint analysis of MDS-005, a multicenter, randomized, placebo controlled phase III study of REVLMID (lenalidomide) compared with placebo in patients with non-del-5q myelodysplastic syndromes (MDS).Says significantly more patients treated with lenalidomide achieved red-blood-cell-transfusion independence (RBC-TI) of at least 56 days compared with placebo (26.9 pct, [43/160 patients] vs. 2.5 pct, [2/79 patients]; p<0.001), the primary endpoint of the study.HRQoL was assessed using European Organization for Research and Treatment of Cancer QLQ-C30 questionnaire at baseline, every 12 weeks thereafter and at discontinuation.Patients who had a score change of at least 1 from baseline were assessed (lenalidomide n=122, placebo n=56).Clinically relevant domains of HRQoL were pre-selected as fatigue, dyspnea, physical functioning, emotional functioning and global quality of life.At week 12, mean changes in HRQoL scores from baseline were not significantly different between treatment arms for the pre-selected domains.At week 24, HRQoL score changes favored lenalidomide versus placebo for all pre-selected domains.After adjusting for baseline scores, improvement was statistically significant for emotional functioning (P=0.047) but not other domains.In lenalidomide patients, those who achieved RBC-TI and/or erythroid response at Week 24, an improving trend was observed with continued lenalidomide treatment.  Full Article

BRIEF-Sanofi, Pfizer, Gilead & Celgene interested in Medivation - CNBC citing sources

* Sanofi, Pfizer, Gilead & Celgene interested in Medivation as company asks for indications of interest by mid-August - CNBC citing sources Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)